United Therapeutics Corporation reported significant financial growth for the three months ended September 30, 2024, with total revenues reaching $748.9 million, marking a 23% increase from $609.4 million in the same period of 2023. This revenue growth was accompanied by a rise in net income, which amounted to $309.1 million, compared to $267.6 million in the prior year. Basic earnings per share also improved, increasing to $6.93 from $5.71.
Operating income for the same quarter was reported at $343.1 million, slightly up from $327.0 million in the previous year. The company’s financial position strengthened, with total current assets rising to $4,000.4 million as of September 30, 2024, up from $3,551.0 million at the end of 2023. Cash and cash equivalents saw a notable increase, reaching $1,553.9 million compared to $1,207.7 million previously.
On the liabilities side, total current liabilities increased to $873.4 million from $804.4 million, while total liabilities overall decreased to $1,022.2 million from $1,182.2 million. Stockholders’ equity also saw an uptick, rising to $6,100.9 million from $5,984.8 million at the end of 2023.
For the nine months ended September 30, 2024, net cash provided by operating activities was $985.9 million, an increase from $827.3 million in the same period of 2023. Additionally, net cash provided by investing activities showed a significant turnaround, amounting to $540.4 million, compared to a negative $761.7 million in the prior year.
As of September 30, 2024, the company had an outstanding balance of $400.0 million under its credit agreement, a reduction from $700.0 million at the end of 2023. United Therapeutics has not elected to use the extended transition period for complying with new or revised financial accounting standards and does not hold shell company status. The number of shares outstanding of common stock as of October 23, 2024, was reported at 44,644,519 shares.
About UNITED THERAPEUTICS Corp
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.